You are here: Industry Insights > Pulmatrix

News List

Pulmatrix Announces Agreement with Lung Cancer Initiative americanpharmaceuticalreview
January 06, 2020
Pulmatrix has entered into a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson. Through the agreement, the Lung Cancer Initiative gains an option to access a portfolio of narrow spectrum kinase inhibitors intended fo
Pulmatrix and Cipla collaborate to develop asthma drug pharmaceutical-technology
April 18, 2019
Pulmatrix and Cipla Technologies have signed a definitive agreement to jointly develop and commercialise Pulmazole to treat allergic bronchopulmonary aspergillosis (ABPA) in asthma patients.
Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole pharmafocusasia
April 03, 2019
Pulmatrix, Inc., a clinical stage biopharmaceutical company focused on developing novel inhaled therapeutics to serve unmet needs in respiratory disease, announced today its entry into a Binding Term Sheet with Cipla Technologies LLC ("Cip Tec")...
Pulmatrix signs binding agreement with Cipla worth $22M biospectrumasia
April 02, 2019
Pulmatrix enters into binding term sheet with Cipla Technologies LLC for the development and commercialization of Pulmazole
Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study americanpharmaceuticalreview
February 14, 2019
Pulmatrix announced the US Food and Drug Administration (FDA) completed its review of our Investigational New Drug (IND) Application and notified the Company that we are authorized to initiate a Phase 2 clinical investigation for ...
Pulmatrix Announces Positive Top-Line Results from Pulmazole Trial americanpharmaceuticalreview
June 27, 2018
Pulmatrix announced top-line results for the ongoing first-in-human study for Pulmazole (PUR1900) – an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for the treatment of allergic
Pulmatrix Announces Pricing Of $15.2 Million Underwritten Public Offering biospace
March 30, 2018
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the pricing of an underwritten public offering of an aggregate of 23,500,000 units.